Wang XK, Yang X, Yao TH, Tao PX, Jia GJ, Sun DX, Yi L, Gu YH. Advances in immunotherapy of M2 macrophages and gastrointestinal stromal tumor. World J Gastrointest Oncol 2024; 16(7): 2915-2924 [PMID: 39072184 DOI: 10.4251/wjgo.v16.i7.2915]
Corresponding Author of This Article
Yuan-Hui Gu, Doctor, Chief Doctor, Surgeon, Surgical Oncologist, Department of General Surgery, Gansu Provincial Hospital, No. 204 Donggang West Road, Lanzhou 730000, Gansu Province, China. guyuanh@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Xiao-Ke Wang, Xin Yang, Tong-Han Yao, The First School of Clinical Medical, Gansu University of Chinese Medicine, Lanzhou 730000, Gansu Province, China
Peng-Xian Tao, Yuan-Hui Gu, Department of General Surgery, Gansu Provincial Hospital, Lanzhou 730000, Gansu Province, China
Guan-Jun Jia, Lin Yi, School of Traditional Chinese and Western Medicine, Gansu University of Chinese Medicine, Lanzhou 730000, Gansu Province, China
Author contributions: Wang XK contributed to original draft preparation; Yang X and Yao TH contributed to image drawing; Jia GJ and Sun DX participated in literature collection; Gu YH, Yi L, and Tao PX revised the manuscript; and all authors wrote, read, and approved the final manuscript. The reasons for designating Gu YH and Yi L as co-corresponding authors are twofold. Gu YH and Yi L were the co-corresponding authors of this manuscript because they discussed and selected topics together and developed the framework of the entire manuscript; after the first draft was completed, they revised and improved the manuscript together and jointly guided the completion of this manuscript.
Supported bythe National Natural Science Foundation of China, No. 82160842; and Clinical Research Project of Research Fund of Gansu Provincial Hospital, No. 23GSSYD-17.
Conflict-of-interest statement: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yuan-Hui Gu, Doctor, Chief Doctor, Surgeon, Surgical Oncologist, Department of General Surgery, Gansu Provincial Hospital, No. 204 Donggang West Road, Lanzhou 730000, Gansu Province, China. guyuanh@163.com
Received: March 18, 2024 Revised: May 16, 2024 Accepted: May 28, 2024 Published online: July 15, 2024 Processing time: 116 Days and 4.5 Hours
Abstract
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal-derived tumors of the GI tract. They can occur throughout the GI tract, and the survival time of some patients can be improved by first-line targeted therapy with imatinib. However, there are some limitations with imatinib treatment. Immunotherapy for GIST has attracted much attention in recent years, and as one of the most abundant cells in the GIST microenvironment, M2 macrophages play an important role in disease progression. They have unique anti-inflammatory and pro-tumorigenic effects and are one target for immunotherapy. This review summarizes the connection between different factors and the programmed death receptor-1/programmed death ligand-1 pathway and M2 macrophages to reactivate or enhance anti-tumor immunity and improve imatinib efficacy, and to provide new ideas for GIST immunotherapy.
Core Tip: The place of imatinib in gastrointestinal stromal tumor (GIST) treatment is indisputable, but it has some limitations and is not accepted by all patients. In this review, we summarize the interaction between M2 macrophages and the programmed death receptor-1/programmed death ligand-1 pathway, which can improve the efficacy of imatinib by reactivating or enhancing the anti-tumor effect of the host immune system and provide new ideas for GIST immunotherapy.
